Literature DB >> 15368324

Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma.

Naoyo Nishida1, Hirohisa Yano, Kan Komai, Takashi Nishida, Toshiharu Kamura, Masamichi Kojiro.   

Abstract

BACKGROUND: The vascular endothelial growth factor (VEGF) family and VEGF receptors (VEGFR) play an essential role in the angiogenesis of both pathologic and nonpathologic conditions. However, the prognostic significance of VEGF and VEGFR expression in ovarian carcinoma is unclear.
METHODS: The tissue expression levels of VEGF-A, VEGF-C, VEGFR-2, and VEGFR-3 in 80 specimens of ovarian carcinoma were examined immnohistochemically. The results obtained were analyzed clinicopathologically.
RESULTS: VEGF-A, VEGF-C, VEGFR-2, and VEGFR-3 were expressed both in tumor cells and in adjacent endothelial cells of blood and lymph vessels. The tissue expressions of VEGF-C and VEGFR-2 were correlated significantly with tumor extension, including peritoneal metastases outside the pelvic cavity (P = 0.0010 and P = 0.0008, respectively), lymph node metastases (P = 0.0030 and P = 0.0018, respectively), and positive ascitic cytology (P = 0.025 and P = 0.0016, respectively). Conversely, there was no significant correlation between VEGF-A and VEGFR-3 expression and clinicopathologic features of ovarian carcinoma. Logistic regression analysis revealed that the expressions of VEGF-C and VEGFR-2 also were independent risk factors for peritoneal and lymph node metastases. Survival curves determined by the Kaplan-Meier method and in univariate analysis demonstrated that high expression levels of VEGF-C and VEGFR-2 were associated with the 5-year survival rate. In multivariate analysis, high expression levels of VEGF-C and VEGFR-2 emerged as independent indicators for disease-specific survival.
CONCLUSIONS: High tissue expression of VEGF-C and VEGFR-2 reflects the aggressiveness of the spread of tumor in ovarian carcinoma. Thus, both have predictive value for identifying high-risk patients who have a poor prognosis. Copyright 2004 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15368324     DOI: 10.1002/cncr.20449

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  37 in total

1.  Functional significance of VEGFR-2 on ovarian cancer cells.

Authors:  Whitney A Spannuth; Alpa M Nick; Nicholas B Jennings; Guillermo N Armaiz-Pena; Lingegowda S Mangala; Christopher G Danes; Yvonne G Lin; William M Merritt; Premal H Thaker; Aparna A Kamat; Liz Y Han; James R Tonra; Robert L Coleman; Lee M Ellis; Anil K Sood
Journal:  Int J Cancer       Date:  2009-03-01       Impact factor: 7.396

2.  VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2.

Authors:  Jaeyoung J Lim; Kun Yang; Barbie Taylor-Harding; W Ruprecht Wiedemeyer; Ronald J Buckanovich
Journal:  Neoplasia       Date:  2014-04       Impact factor: 5.715

3.  Ovarian cancer development and metastasis.

Authors:  Ernst Lengyel
Journal:  Am J Pathol       Date:  2010-07-22       Impact factor: 4.307

Review 4.  Angiogenesis and ovarian cancer.

Authors:  César Gómez-Raposo; Marta Mendiola; Jorge Barriuso; Enrique Casado; David Hardisson; Andrés Redondo
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

5.  No association of vascular endothelial growth factor-A (VEGF-A) and VEGF-C expression with survival in patients with gastric cancer.

Authors:  Soo Jung Lee; Jong Gwang Kim; Sang Kyun Sohn; Yee Soo Chae; Joon Ho Moon; Shi Nae Kim; Han-Ik Bae; Ho Young Chung; Wansik Yu
Journal:  Cancer Res Treat       Date:  2009-12-31       Impact factor: 4.679

6.  Kaempferol inhibits angiogenesis and VEGF expression through both HIF dependent and independent pathways in human ovarian cancer cells.

Authors:  Haitao Luo; Gary O Rankin; Lingzhi Liu; Matthew K Daddysman; Bing-Hua Jiang; Yi Charlie Chen
Journal:  Nutr Cancer       Date:  2009       Impact factor: 2.900

7.  Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice.

Authors:  Hanna Sallinen; Maarit Anttila; Johanna Narvainen; Jonna Koponen; Kirsi Hamalainen; Ivana Kholova; Tommi Heikura; Pyry Toivanen; Veli-Matti Kosma; Seppo Heinonen; Kari Alitalo; Seppo Yla-Herttuala
Journal:  Mol Ther       Date:  2008-12-02       Impact factor: 11.454

8.  Lymphangiogenesis and prognostic significance of vascular endothelial growth factor C in gastro-oesophageal junction adenocarcinoma.

Authors:  Liang-Xi Xie; Tian-Tian Zhai; Li-Ping Yang; Eleanor Yang; Xiao-Hui Zhang; Jiong-Yu Chen; Hao Zhang
Journal:  Int J Exp Pathol       Date:  2013-02       Impact factor: 1.925

9.  Preoperative serum levels of serum VEGF-C is associated with distant metastasis in colorectal cancer patients.

Authors:  Andrew A Alabi; Aravind Suppiah; Leigh A Madden; John R Monson; John Greenman
Journal:  Int J Colorectal Dis       Date:  2008-12-16       Impact factor: 2.571

Review 10.  Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis.

Authors:  Tsz-Lun Yeung; Cecilia S Leung; Kay-Pong Yip; Chi Lam Au Yeung; Stephen T C Wong; Samuel C Mok
Journal:  Am J Physiol Cell Physiol       Date:  2015-07-29       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.